source
- STAT+: Are analysts too quick to gloss over Lilly’s liver case?Cytokinetics' Myqorzo's trial results, Johnson & Johnson's IBD therapy, and more biotech news from The ReadoutSTAT · 3mo ago↗ source
- Microbiome startup raises $48M for immunotherapy and malnutrition treatmentsScientists trying to understand why cancer immunotherapy works so well for some patients and not others have found a potential answer in one cancer survivor's poop. A biotech startup has studied th…Endpoints · 3mo ago↗ source
- J&J's IBD combo fails Phase 2 studies, but will move into pivotal testingJohnson & Johnson will move a treatment for inflammatory bowel disease into Phase 3 studies despite the therapy's failure in two mid-stage trials. The company said that JNJ-4804, a combination of t…